ImmuPharma (LON:IMM) Stock Price Down 1.7% - Here's Why

Key Points

• ImmuPharma plc shares fell by 1.7% to GBX 11.90 ($0.16) during mid-day trading, with the stock traded volume increasing by 2% from average levels.
• The company reported a negative P/E ratio of -1,276.97 and is projected to post earnings per share of -339.00 for the current fiscal year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with their lead product being Lupuzor™, aimed at treating Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 1.7% during mid-day trading on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 11.90 ($0.16). 8,737,517 shares changed hands during trading, an increase of 2% from the average session volume of 8,564,530 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Price Performance

The stock has a market capitalization of £56.79 million, a P/E ratio of -1,276.97 and a beta of 1.53. The company's 50 day simple moving average is GBX 4.66 and its two-hundred day simple moving average is GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.